Dr. Matthew L. Flaherty, MD
Neurology (Vascular Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 84
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Vascular Neurology Physician primary
OH license 35.082928 -
Neurology Physician
KY license 37855 · OH license 35082928
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
- West Chester Hospital West Chester, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 84
- Services billed
- 204
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 25 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 11 |
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 19 |
| Hospital discharge day management, 30 minutes or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 46 |
| Levetiracetam Other prescribers in Cincinnati, OH | 46 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Cincinnati, OH | 38 |
| Atorvastatin Calcium Other prescribers in Cincinnati, OH | 28 |
| Lamotrigine Other prescribers in Cincinnati, OH | 23 |
| Brilinta (ticagrelor) Other prescribers in Cincinnati, OH | 22 |
| Ezetimibe Other prescribers in Cincinnati, OH | 20 |
| Pregabalin Other prescribers in Cincinnati, OH | 16 |
| Gabapentin Other prescribers in Cincinnati, OH | 16 |
| Topiramate Other prescribers in Cincinnati, OH | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $750 in total to this clinician.
| Csl Behring | $750 |
|---|
| Compensation for services other than consulting (speaking, faculty) | $750 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Csl Behring Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) Kcentra · Trauma (Emergency, Injury, Surgery) | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $66,748 in research payments for these studies, mostly to the institutions running them.
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.